Trial intelligence / Profile preview

Inhaled AZD8683 in COPD

NCT01205269Phase 2Completed

Sponsor
AstraZeneca
Start
Oct 2010
Primary completion
Dec 2010
Modality
Small Molecules
Countries
1
01

Overview

A Phase 2 trial of AZD8683 in chronic obstructive pulmonary disease (COPD), sponsored by AstraZeneca. Started Oct 2010; status: completed.

02

Drugs

AZD8683
03

Conditions

chronic obstructive pulmonary disease (COPD)

Beyond the preview

Go deeper on NCT01205269.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on NCT01205269.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call